Palvella Therapeutics, Inc.
PVLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.77 | 0.09 | -0.01 | 0.03 |
| FCF Yield | 0.00% | -2.18% | -10.86% | -20.19% |
| EV / EBITDA | 1,842.26 | -23.80 | 1.91 | 13.03 |
| Quality | ||||
| ROIC | -17.97% | -14.42% | -11.17% | -5.73% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | – | 0.57 | 0.83 | 1.36 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 100.00% | 19.71% | -25.50% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -185.87 | 6.89 | 10.85 | 19.15 |
| Interest Coverage | -6.74 | -6.83 | -6.48 | -3.35 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |